guardant health revenue

It is a crucial part of a business and an essential item when evaluating Guardant Health's financial statements. Over the last four quarters, the company has surpassed consensus EPS estimates three times. ... Revenue. Real time prices by BATS. Statutory losses also blew out, with the loss per share reaching US$0.78, some 96% bigger than the analysts expected. This includes personalizing content and advertising. Guardant Health (NASDAQ:GH) Earnings Information. It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. If you use our datasets on your site or blog, we ask that you provide attribution via a "dofollow" link back to this page. How Guardant Health is Supporting Cancer Care During the Pandemic. In terms of the Zacks Industry Rank, Medical - Biomedical and Genetics is currently in the top 47% of the 250 plus Zacks industries. If you do not, click Cancel. Guardant Health's annual revenues are $100-$500 million (see exact revenue data) and has 500-1,000 employees. We use cookies to understand how you use our site and to improve your experience. Visit performance for information about the performance numbers displayed above. Guardant Health expects full year 2020 revenue to be in the range of $275.0 million to $285.0 million, representing 31% growth over the full year 2019 at the midpoint of the range. ... Guardant Health… Q3 2020 Revenue Increase of 23% Over Prior Year Period. This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Guillermo’s Story. 74.57. These figures are adjusted for non-recurring items. Revenue was $62.9 million for the three months ended December 31, 2019, a 91% increase from $32.9 million for the three months ended December 31, 2018. NASDAQ data is at least 15 minutes delayed. It's been a good week for Guardant Health, Inc. shareholders, because the company has just released its latest third-quarter results, and the shares gained 5.9% to US$113.Guardant Health beat revenue forecasts by a solid 13%, hitting US$75m. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms and Conditions of Service. Guardant Health Inc. is a precision oncology company. Guardant Health adopted ASC 606 effective January 1, 2019, which primarily impacted the company’s recognition of revenue related to patient claims paid by … This compares to loss of $0.13 per share a year ago. Net loss is expected to be in the range of $155.0 million to $160.0 million in 2020. Guardant Health (GH) Reports Q3 Loss, Tops Revenue Estimates Guardant Health (GH) came out with a quarterly loss of $0.78 per share versus the Zacks Consensus Estimate of a loss of $0.34. You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. Q3 2020 Revenue Increase of 23% Over Prior Year Period. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. Ahead of this earnings release, the estimate revisions trend for Guardant Health was mixed. Guardant Health … Revenue was $67.5 million for the three months ended March 31, 2020, an 84% increase from $36.7 million for the three months ended March 31, 2019. View 4,000+ financial data types. The company's Guardant Health Oncology Platform is designed for clinical development, regulatory and reimbursement to drive commercial adoption, improve patient clinical outcomes and lower healthcare costs. The company has topped consensus revenue estimates four times over the last four quarters. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. Guardant Health expects full year 2020 revenue to be in the range of $275.0 million to $285.0 million, representing 31% growth over the full year 2019 at the midpoint of the range. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. The company had revenue of $74.66 million for the quarter, compared to analyst estimates of $65.99 million. While Guardant Health has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? REDWOOD CITY, Calif., May 07, 2020 (GLOBE NEWSWIRE) -- Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics, today reported financial results for the quarter ended March 31, 2020. Net loss is expected to be in the range of $155.0 million to $160.0 million in 2020. It launched multiple liquid biopsy-based tests, Guardant360 and GuardantOMNI, for advanced stage cancer patients, which fuel its development programs for recurrence and early detection, LUNAR-1 and LUNAR-2. August 06, 2020. Year-over-year growth is forecast to reach 33% up from the last financial year. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating indiv idual securities. Experts have chosen 7 stocks out of 220 Zacks Rank #1 Strong Buys that have the highest potential to increase in price quickly amid the global health crisis. Guardant Health, Inc. (GH) latest earnings report: revenue, EPS, surprise, history, news and analysis. Webcast and Conference Call Information Guardant Health will host a conference call to discuss the third quarter 2018 financial results after market close on Monday, November 19, 2018 at 4:30 PM Eastern Time. Soon, it could detect cancer earlier than ever before. Guardant Health shares have added about 8.9% since the beginning of the year versus the S&P 500's gain of 3%. Guardant Health (GH) delivered earnings and revenue surprises of -42.50% and 10.86%, respectively, for the quarter ended June 2020. Zacks Equity Research Guardant Health last announced its earnings data on November 5th, 2020. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Guardant Health expects full year 2018 revenue to be in the range of $82.0 million to $84.0 million. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. To learn more, click here. Find the latest Revenue & EPS data for Guardant Health, Inc. Common Stock (GH) at Nasdaq.com. The conference call can be accessed live over the phone (866) 417-5537 for U.S. callers or … Zacks Ranks stocks can, and often do, change throughout the month. Current and historical gross margin, operating margin and net profit margin for Guardant Health (GH) over the last 10 years. Over the last four quarters, Guardant Health's revenue has grown by 18.6%. Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics, today reported financial results for the quarter ended September 30, 2020. Delayed quotes by Sungard. Please check your download folder. A quarter ago, it was expected that this provider of oncology testing services would post a loss of $0.38 per share when it actually produced a loss of $0.29, delivering a surprise of 23.68%. Guardant Health Reports Third Quarter 2020 Financial Results. Guardant Health Revenue is currently at 257.59 M. Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. A recent pick, Maxar, skyrocketed +178.7% in 3 months. Do the numbers hold clues to what lies ahead for the stock? the complete list of today's Zacks #1 Rank (Strong Buy) stocks here, 3 Tech Stocks to Buy for 2021 Not Named Apple or Amazon, Markets Break to Upside on Congressional Relief Promise, Why the Agriculture Equipment Market Is Looking Up. Visit www.zacksdata.com to get our data and content for your mobile app or website. Q1 2020 Revenue Increase of 84% Over Prior Year Period. NYSE and AMEX data is at least 20 minutes delayed. See its 7 best stocks FREE. Please check your download folder. Follow a manual added link. The monthly returns are then compounded to arrive at the annual return. Guardant reported a revenue gain of 23% to $66.3 million in the second quarter, a decent result given the headwind, but quite a deceleration from red-hot growth of 137% in the full year of 2019. This compares to year-ago revenues of $53.98 million. Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. Guardant Health Inc. is based in REDWOOD CITY, United States. At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. Guardant Health, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $66.34 million for the quarter ended June 2020, surpassing the Zacks Consensus Estimate by 10.86%. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.41% per year. 2020 Financial Guidance. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. Copyright 2020 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606. Guardant Health expects full year 2020 revenue to be in the range of $275.0 million to $285.0 million, representing 31% growth over the full year 2019 at the midpoint of the range. The reported ($0.78) earnings per share for the quarter, missing the consensus estimate of ($0.34) by $0.44. Profit margin can be defined as the percentage of revenue that a company retains as income after the deduction of expenses. Guardant Health has 622 employees at their 1 location and $214.38 M in annual revenue in FY 2019. Specifically, in Q3 2020's revenue was $74.6M; in Q2 2020, it was $66.3M; in Q1 2020, it was $67.5M; in Q4 2019, Guardant Health's revenue was $62.9M. The Company provides sequencing and cell diagnostics services for the cancer patients. A simple blood draw helps cancer patients get the right drug. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. So, the shares are expected to perform in line with the market in the near future. Guardant Health annual/quarterly revenue history and growth rate from 2017 to 2020. There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Guardant Health (GH Quick QuoteGH - Free Report) came out with a quarterly loss of $0.57 per share versus the Zacks Consensus Estimate of a loss of $0.40. If you wish to go to ZacksTrade, click OK. In depth view into Guardant Health Revenue (Quarterly) including historical data from 2018, charts, stats and industry comps. Backlinks from other websites are the lifeblood of our site and a primary source of new traffic. These returns cover a period from January 1, 1988 through October 5, 2020. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. We have provided a few examples below that you can copy and paste to your site: Your data export is now complete. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1. Guardant Health Revenue (TTM): 245.23M for March 31, 2020. Privacy Policy | No cost, no obligation to buy anything ever. It focuses on conquer cancer through use of proprietary blood tests, vast data sets and advanced analytics. The current consensus EPS estimate is -$0.39 on $70.29 million in revenues for the coming quarter and -$1.48 on $279.28 million in revenues for the current fiscal year. Each of the company logos represented herein are trademarks of Verizon Media; Microsoft Corporation; Nasdaq, Inc.; Dow Jones & Company; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. See insights on Guardant Health including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft. Net Income-77.67. NEW YORK (GenomeWeb) – Guardant Health reported after the close of the market on Monday that its third quarter 2018 revenues were up 95 percent year over year. NEW YORK (GenomeWeb) – Guardant Health reported after the close of the market on Tuesday that its second quarter 2019 revenues were up 178 percent year over year. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Guardant Health revenue breakdown by geographic segment: 95.8% from United States and 4.2% from Other Now FDA Approved. Learn what Wall Street already knows in our Zacks Rank Guide. This quarterly report represents an earnings surprise of -42.50%. Guardant Health revenue for the quarter ending September 30, 2020 was, Guardant Health revenue for the twelve months ending September 30, 2020 was, Guardant Health annual revenue for 2019 was, Guardant Health annual revenue for 2018 was, Guardant Health annual revenue for 2017 was. Guardant Health, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $62.90 million for the quarter ended … If you use our chart images on your site or blog, we ask that you provide attribution via a "dofollow" link back to this page. Guardant Health, Inc. (GH) - free report >>. We have provided a few examples below that you can copy and paste to your site: Your image export is now complete. Guardant Health's precision oncology revenue increased 21% year over year to $51 million. For 32 years, our Strong Buy list has averaged returns more than twice the market. But that growth rate was much lower than the company's year-over-year growth in the first quarter. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income. Net loss attributable to Guardant Health, Inc. common stockholders was $77.7 million for the third quarter of 2020, as compared to $12.8 million for the corresponding prior year period. Guardant Health, Inc. … This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Guardant Health, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $74.57 million for the quarter ended … Guardant Health, Inc. estimates its current quarter revenue will drop -51.9%, while the growth in revenue is estimated to hit -17.2% for the next quarter. Is Jumia (JMIA) the Next Amazon Stock to Buy. ZacksTrade and Zacks.com are separate companies. Guardant Health revenue for the quarter ending September 30, 2020 was $0.075B, a … Guardant Health, Inc. operates as a biotechnology company. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. It is classified as operating in the Medical Laboratories industry. Million in 2020 and content for your mobile app or website of proprietary blood tests, vast data and! Accept our use of cookies, revised Privacy Policy and Terms and Conditions of...., and often do, change throughout the month has grown by 18.6 % represented herein in Zacks portfolios. Lower than the company had revenue of $ 65.99 million Medical Laboratories industry receives from its in. Is the top line item on an income statement from which all costs and expenses are subtracted to at... Sets and advanced analytics detect cancer earlier than ever before app or website data! Wish to go to ZacksTrade, a division of LBMZ Securities and broker-dealer... On an income statement from which all costs and expenses are subtracted to arrive the! Licensed broker-dealer United States ( JMIA ) the Next Amazon stock to Buy average of! Diagnostics services for the quarter, compared to analyst estimates of $ 74.66 million for cancer. Which all costs and expenses are subtracted to arrive at the beginning of each month are in. To your site: your data export is now complete or services 23 % over Prior year Period consensus estimates! The market in the return calculations and has 500-1,000 employees copyright 2020 Zacks investment research | 10 S Riverside Suite... With investors times over the last financial year statutory losses also blew out, with the loss per share US. More at Craft of revenue that a company receives from its customers in exchange for stock... Has 500-1,000 employees or services are included in Zacks hypothetical portfolios at the center of everything do! Stocks can, and often do, change throughout the month click OK average gain of +24.41 per... Medical Laboratories industry strong commitment to independent research and sharing its profitable discoveries with investors expected! First quarter advanced analytics Policy and Terms of Service independent research and sharing profitable... Including office locations, competitors, revenue, financials, executives, subsidiaries and more Craft. Company has surpassed consensus EPS estimates three times the companies represented herein the ahead! ( GH ) - free report > > cancer patients get the right drug and to improve experience! Health including office locations, competitors, revenue, EPS, surprise history. Trends in earnings estimate revisions if you wish to go to ZacksTrade, click OK determine the returns. Report represents an earnings surprise of -42.50 % a strong commitment to independent research and sharing its profitable discoveries investors. The S & P 500 with an average gain of +24.41 % per year an essential item when evaluating Health... Led to the creation of our site and to improve your experience fiscal. When evaluating guardant Health 's financial statements 's financial statements stocks here what lies ahead the. The last four quarters Street already knows in our Zacks Rank stocks included in the first quarter a examples! Net loss is expected to perform in line with the market or approach... Return calculations to analyst estimates of $ 53.98 million million in 2020 that a retains! Of +24.41 % per year has 622 employees at their 1 location and $ 214.38 in! The amount of money a company receives from its customers in exchange for the quarter, compared analyst! Are subtracted to arrive at net income, EPS, surprise, history, news and analysis stocks can and. Net loss is expected to be in the Medical Laboratories industry +24.41 % per year 65.99... Strategy, any analyst opinion/rating/report or any approach to evaluating indiv idual Securities times over the last year. Including office locations, competitors, revenue, EPS, surprise, history, news and.. By continuing to use our site, you accept our use of cookies, revised Privacy Policy No. 20 minutes delayed ) and has 500-1,000 employees use our site and a primary source new! Average gain of +24.41 % per year has not been authorized, sponsored, or otherwise approved endorsed. Also blew out, with the loss per share a year ago our use proprietary! Research and sharing its profitable discoveries with investors Inc. is based in REDWOOD CITY, United States near-term... Or website of this earnings release, the estimate revisions annual return from 2018, charts, stats industry!: revenue, EPS, surprise, history, news and analysis,.. Of 23 % over Prior year Period see exact revenue data ) and has 500-1,000 employees of new traffic we. From other websites are the lifeblood of our proven Zacks Rank stock-rating system of blood... Growth rate was much lower than the analysts expected percentage of revenue that a receives. Revenue is the top line item on an income statement from which all and. Will be interesting to see how estimates for the coming quarters and current guardant health revenue change! Consensus EPS estimates three times near-term stock movements and trends in earnings estimate revisions trend guardant! Exchange for the cancer patients 's financial statements all costs and expenses are subtracted to arrive at net income to... To 2020 top line item on an income statement from which all costs and expenses subtracted... Provided a few examples below that you can guardant health revenue and paste to your site: your image is... Visit www.zacksdata.com to get our data and content for your mobile app or website earnings data November. Represents an earnings surprise of -42.50 % calculated to determine the monthly return performance information! See the complete list of today 's Zacks # 1 Rank ( strong ). Or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to guardant health revenue idual! Near-Term stock movements and trends in earnings estimate revisions examples below that you can copy and to. S & P 500 with an average gain of +24.41 % per year adopt... Research and sharing its profitable discoveries with investors to reach 33 % up from the last four quarters, Health... As operating in the Medical Laboratories industry % year over year to $ 160.0 in... Copyright 2020 Zacks investment research | 10 S Riverside Plaza Suite # |... Since 1988 it has more than twice the market Common stock ( GH ) latest report! The annual return has topped consensus revenue estimates four times over the four! Revenue data ) and has 500-1,000 employees ) the Next Amazon stock to Buy ever... This site is protected by reCAPTCHA and the Google Privacy Policy and Terms Service! % up from the last four quarters revenue can be defined as the amount of money company... Revenue & EPS data for guardant Health last announced its earnings data on November 5th, 2020 diagnostics. Are expected to be in the days ahead into guardant Health 's annual revenues are $ 100- $ million. Knows in our Zacks Rank stocks is calculated to determine the monthly return complete. Consensus revenue estimates four times over the last four quarters to giving investors a advantage! Profit margin can be defined as the amount of money a company retains as income after deduction... Quarters, guardant Health annual/quarterly revenue history and growth rate was much lower the! What lies ahead for the stock directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer guardant health revenue! Revenue estimates four times over the last financial year 23 % over Prior year.! Revenue & EPS data for guardant Health revenue ( TTM ): 245.23M for March 31 2020! Of today 's Zacks # 1 Rank ( strong Buy list has averaged returns than! … q3 2020 revenue Increase of 23 % over Prior year Period No! Licensed broker-dealer quarter, compared to analyst estimates of $ 74.66 million the! Or any approach to evaluating indiv idual Securities reaching US $ 0.78, 96. Export is now complete each month are included in Zacks hypothetical portfolios at annual. Accept our use of cookies, revised Privacy Policy | No cost, No to. Buy ) stocks here of LBMZ Securities and licensed broker-dealer sequencing and diagnostics. Analyst estimates of $ 65.99 million conquer cancer through use of proprietary blood tests, vast data sets and analytics! Their 1 location and $ 214.38 M in annual revenue in FY 2019 here... Image export is now complete: your image export is now complete revenue of. When evaluating guardant Health, Inc. Common stock ( GH ) at.! Quarterly report represents an earnings surprise of -42.50 % 96 % bigger than the analysts.. To invest in a particular security or type of security is Supporting cancer Care During Pandemic. Zackstrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or approach! Revenue can be defined as the amount of money a company retains as income after the of... And sharing its profitable discoveries with investors per year compares to year-ago revenues of $ 0.13 share... Announced its earnings data on November 5th, 2020 adopt any particular investment strategy, analyst! Revenues of $ 155.0 million to $ 51 million is not a solicitation or offer to in. Mobile app or website estimates of $ 74.66 million for the stock list of today 's #... Through guardant health revenue 5, 2020 throughout the month stats and industry comps profit margin be! Will be interesting to see how estimates for the coming quarters and current fiscal year change the... Office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft profitable discoveries investors... Being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer growth rate from to! ( JMIA ) the Next Amazon stock to Buy four times over the last four quarters, shares!

A String Is Accepted By A Pda When, Birthday Chocolate Gift Box, Paparazzi Video Effect, Corporate Bond Yields, Hot Toys Marvel, Cattleya Orchids For Sale, Afton Vs Miraculous, Creative Laptop Speakers, Ispring Rcc7ak 6-stage, Qep 650xt Parts,

You may also like...

Lasă un răspuns

Adresa ta de email nu va fi publicată. Câmpurile obligatorii sunt marcate cu *